The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema

Inclusion Criteria:

Inclusion criteria for patients with nAMD

• A diagnosis of nAMD

• Patient aged ≥50 years

• Patients for whom the decision to initiate treatment with intravitreal (IVT)aflibercept 8 mg according to a local product information was made as part ofroutine clinical practice

• Signed informed patient consent before the start of data collection (according tothe requirements of the local authorities and laws)

Inclusion criteria for patients with DME

• A diagnosis of DME

• Patient aged ≥18 years (or country's legal age of adulthood if the legal age is >18years) with type 1 or type 2 diabetes mellitus

• Patients for whom the decision to initiate treatment with IVT aflibercept 8 mgaccording to a local product information was made as part of routine clinicalpractice

• Signed informed patient consent before the start of data collection (according tothe requirements of the local authorities and laws)

Exclusion Criteria:

Exclusion criteria for all patients with nAMD

• Participation in an investigational program with interventions outside of clinicalroutine practice

• Contraindications as listed in the local intravitreal aflibercept 8 mg local productinformation

• Extra/periocular infection or inflammation in either eye at time of first injection

• Patient receiving other intravitreal treatments other than aflibercept in the felloweye

• Any medication interfering with aflibercept 8 mg in the intravitreal aflibercept 8mg local product information Additional exclusion criteria for treatment-naïvepatients with nAMD

• Any prior ocular treatment in the study eye or systemic treatment in nAMD Additionalexclusion criteria for pretreated patients with nAMD

• Prior intravitreal anti-VEGF treatments in the study eye within the last 28 days

• Prior treatment with intravitreal corticosteroid in the study eye within the last 3months

• Fluocinolone implant in the study eye within the last 3 years

• Dexamethasone implant in the study eye within the last 6 months

• Any concurrent drug releasing implant in the study eye

Exclusion criteria for all patients with DME

• Participation in an investigational program with interventions outside of clinicalroutine practice

• Contraindications as listed in the intravitreal aflibercept 8 mg local productinformation

• Extra/periocular infection or inflammation in either eye at time of first injection

• Patient receiving other intravitreal treatments other than aflibercept in the felloweye

• Any medication interfering with aflibercept 8 mg in the intravitreal aflibercept 8mg local product information

• Previous treatment of the study eye with laser in the last 90 days prior to firstIVT aflibercept 8 mg Additional exclusion criteria for treatment-naïve patients withDME

• Any prior ocular treatment in the study eye or systemic treatment in DME Additionalexclusion criteria for pretreated patients with DME

• Prior intravitreal anti-VEGF treatments in the study eye within the last 28 days

• Prior treatment with intravitreal corticosteroid in the study eye within the last 3months

• Fluocinolone implant in the study eye within the last 3 years

• Dexamethasone implant in the study eye within the last 6 months

• Any concurrent drug releasing implant in the study eye